DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1971)

Male Hypogonadism | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Male Hypogonadism | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Male hypogonadism (low testosterone) is a condition characterized by impaired spermatogenesis and low serum testosterone. In adult men, low testosterone can be caused by intrinsic abnormalities in the testes or changes in pituitary or hypothalamic upstream signaling pathways contributing to testosterone biosynthesis. Age and comorbidity (e.g., obesity or type 2 diabetes) driven declines in testosterone levels represent the majority of cases of low testosterone in adult men. Testosterone replacement therapy (TRT), which aims to increase overall serum testosterone levels, is the cornerstone therapy for low testosterone and is primarily administered via injection or topical means. However, a key drawback of TRTs is decreased spermatogenesis, and some alternative therapies for low testosterone focus on the stimulation of gonadotropins in effort to preserve fertility. Additionally, the FDA has recently cautioned against the use of TRT due to the possibility of increased cardiac risk, and this study will evaluate potential changes to physician prescribing and treatment strategies through real-world data analyses.


  • What patient share do key drug classes garner by line of therapy in newly diagnosed patients with male hypogonadism (low testosterone)?
  • How are topical TRTs, injectable TRTs, and other TRT formulations being used in the management of this condition?
  • What proportion of patients with low testosterone receive drug therapy within a year of diagnosis, and how quickly after diagnosis?
  • What percentage of patients progress to later lines of therapy within a year of diagnosis?
  • What are the drug class-level compliance and persistency rates among drug-treated patients?


Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
    • Treatment Algorithms Claims Data Analysis Male Hypogonadism US January 2019

Already a Client? Log in to access this report.

  • Pub Date: January 2019
  • Author(s): Michael Breen, PhD
  • Michael is a business insights analyst on the Infectious, Niche, and Rare Diseases team. He has authored reports on cystic fibrosis, nonalcoholic steatohepatitis, vaccines, and  respiratory syncytial virus, and will author a report on cytomegalovirus. He also provides coverage for Decision Resources’ Company & Drug Insights covering anti-infectives, vaccines, and transplant therapy areas. Michael received his Bachelor’s degree from Hunter College with a dual major in biology and biochemistry. He received his in biochemistry from Boston University School of Medicine. His postdoctoral research was carried out at Brigham and Women’s Hospital/Harvard Medical School, with a focus on identifying novel pathways regulating thermogenesis in search of a therapeutic for obesity and diabetes.

Purchase Report

Recent reports:
You may also be interested in: